Renalytix Plc Stock Börse Stuttgart
Equities
2O9
GB00BYWL4Y04
Advanced Medical Equipment & Technology
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.19 EUR | 0.00% | +6.15% | +12.43% |
Jun. 14 | Renalytix's Diabetes, Kidney Disease Test Gets Medicare Final Coverage Determination | MT |
Jun. 14 | Renalytix Secures Medicare's Final Local Coverage Determination for Kidney Disease Test | MT |
Sales 2024 * | 2.5M 2.34M | Sales 2025 * | 6.98M 6.53M | Capitalization | 34.24M 32.06M |
---|---|---|---|---|---|
Net income 2024 * | -32M -29.96M | Net income 2025 * | -24M -22.47M | EV / Sales 2024 * | 13.7 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 4.91 x |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 61.53% |
Latest transcript on Renalytix Plc
1 week | +6.15% | ||
Current month | +13.77% | ||
1 month | -22.13% | ||
3 months | -51.03% | ||
6 months | +29.25% | ||
Current year | +12.43% |
Managers | Title | Age | Since |
---|---|---|---|
James McCullough
FOU | Founder | 56 | 18-03-14 |
Howard Doran
PSD | President | 63 | 23-08-31 |
Fergus Fleming
CTO | Chief Tech/Sci/R&D Officer | 57 | 18-03-14 |
Members of the board | Title | Age | Since |
---|---|---|---|
Daniel Levangie
BRD | Director/Board Member | 73 | 21-08-29 |
Chairman | 72 | 18-03-14 | |
James McCullough
FOU | Founder | 56 | 18-03-14 |
Date | Price | Change |
---|---|---|
24-06-21 | 0.19 | 0.00% |
24-06-20 | 0.19 | -0.52% |
24-06-19 | 0.191 | 0.00% |
24-06-18 | 0.191 | -10.75% |
24-06-17 | 0.214 | 0.00% |
Delayed Quote Börse Stuttgart, June 21, 2024 at 03:17 am EDT
More quotesQuarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-34.93% | 14.7B | |
-52.73% | 2.33B | |
+24.29% | 1.96B | |
-8.30% | 1.52B | |
+21.24% | 1.24B | |
-21.39% | 904M | |
-34.32% | 750M | |
+1.33% | 784M | |
-28.73% | 597M |
- Stock Market
- Equities
- RENX Stock
- 2O9 Stock